PharmaResearch Co Ltd banner
P

PharmaResearch Co Ltd
KOSDAQ:214450

Watchlist Manager
PharmaResearch Co Ltd
KOSDAQ:214450
Watchlist
Price: 313 500 KRW -2.64% Market Closed
Market Cap: ₩3.3T

PharmaResearch Co Ltd
Cash & Cash Equivalents

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

PharmaResearch Co Ltd
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
P
PharmaResearch Co Ltd
KOSDAQ:214450
Cash & Cash Equivalents
₩142.7B
CAGR 3-Years
25%
CAGR 5-Years
40%
CAGR 10-Years
25%
Celltrion Inc
KRX:068270
Cash & Cash Equivalents
₩1.1T
CAGR 3-Years
27%
CAGR 5-Years
10%
CAGR 10-Years
22%
O
OliX Pharmaceuticals Inc
KOSDAQ:226950
Cash & Cash Equivalents
₩6.4B
CAGR 3-Years
9%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
V
Voronoi Inc
KOSDAQ:310210
Cash & Cash Equivalents
₩10.2B
CAGR 3-Years
-18%
CAGR 5-Years
57%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Cash & Cash Equivalents
₩66.4B
CAGR 3-Years
13%
CAGR 5-Years
11%
CAGR 10-Years
25%
A
ABL Bio Inc
KOSDAQ:298380
Cash & Cash Equivalents
₩112B
CAGR 3-Years
65%
CAGR 5-Years
22%
CAGR 10-Years
N/A
No Stocks Found

PharmaResearch Co Ltd
Glance View

Market Cap
3.3T KRW
Industry
Biotechnology

In the competitive landscape of the biopharmaceutical industry, PharmaResearch Co Ltd. has carved a niche for itself by focusing on developing and commercializing cutting-edge regenerative medicine products. Rooted in South Korea, the company leverages its proprietary technologies to craft biotherapeutics that address unmet medical needs, primarily targeting chronic diseases and tissue repair. Central to its operations is their flagship product line based on platelet-rich plasma (PRP) technology, which has gained traction in the medical community for its efficacy in promoting healing and reducing recovery time. Through strategic partnerships and a robust R&D pipeline, PharmaResearch ensures its continued presence at the forefront of regenerative medicine. The company's revenue model is anchored in a multi-pronged approach that combines product sales, licensing agreements, and collaborative research ventures. By cultivating relationships with healthcare providers and hospitals, PharmaResearch supplies its innovative PRP kits and other regenerative solutions that are used in a variety of clinical settings, from orthopedic to dermatology practices. Furthermore, the company licenses its proprietary technologies to international partners, generating steady streams of royalties. By maintaining a strategic balance between domestic market penetration and global outreach, PharmaResearch Co Ltd. adeptly navigates the complexities of the biopharmaceutical sector while broadening its financial horizon.

Intrinsic Value
514 612.85 KRW
Undervaluation 39%
Intrinsic Value
Price ₩313 500
P

See Also

What is PharmaResearch Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
142.7B KRW

Based on the financial report for Dec 31, 2025, PharmaResearch Co Ltd's Cash & Cash Equivalents amounts to 142.7B KRW.

What is PharmaResearch Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
25%

Over the last year, the Cash & Cash Equivalents growth was -14%. The average annual Cash & Cash Equivalents growth rates for PharmaResearch Co Ltd have been 25% over the past three years , 40% over the past five years , and 25% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett